Retina (Philadelphia, Pa.) · 2026
IN-HUMAN FEASIBILITY AND SAFETY OF SUBRETINAL DRUG INJECTION THROUGH ATTACHED RETINA USING A ROBOTIC COMANIPULATION SYSTEM.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
De Clerck Ivo, Schoovaerts Maarten, Polidoro Martina, Ourak Mouloud, Vander Poorten Emmanuel, Stalmans Peter
Аннотация
PURPOSE: To evaluate feasibility and safety of robot-assisted subretinal injections through attached retina using the comanipulated Mynutia system in patients with submacular hemorrhage.
METHODS: This prospective, single-center case series included 20 eyes undergoing vitrectomy with subretinal recombinant tissue plasminogen activator between June 2024 and August 2025. The EVA Inicio microinjection system with a 38-G needle was mounted on the Mynutia system. Injections were performed through attached retina when feasible. Primary outcomes were successful needle insertion, stable subretinal positioning for ≥3 minutes, safe withdrawal, and absence of device-associated adverse events (DAE). Secondary outcomes included injection parameters, hemorrhage displacement, visual outcomes, and complications.
RESULTS: Robot-assisted injection succeeded in all eyes; one required injection into the submacular hemorrhage because of anatomy. Mean injection duration was 178 ± 34 seconds (max 400), but the needle tip was maintained in the subretinal space ≥3 minutes in all cases. No DAE occurred. Retinotomies closed spontaneously without visible reflux. Mean bleb initiation and propagation pressures were 10.3 ± 3.2 and 3.0 [3.0-3.25] PSI, respectively; internal limiting membrane peeling reduced initiation pressure ( P < 0.05). Complete subfoveal displacement was achieved in 95%. Median BCVA improved from LogMAR 1.85 (counting fingers) to 0.66 (20/90) at 6 weeks ( P < 0.001). Adverse events included hyphema (5%), ocular hypertension (5%), vitreous hemorrhage (25%; 80% self-limited), RPE tear (20%), and recurrent submacular hemorrhage (5%).
CONCLUSION: Robot-assisted subretinal injection with Mynutia is feasible and safe, enabling stable, prolonged low-pressure delivery through attached retina, and may enhance precision and tissue preservation in subretinal therapies.
METHODS: This prospective, single-center case series included 20 eyes undergoing vitrectomy with subretinal recombinant tissue plasminogen activator between June 2024 and August 2025. The EVA Inicio microinjection system with a 38-G needle was mounted on the Mynutia system. Injections were performed through attached retina when feasible. Primary outcomes were successful needle insertion, stable subretinal positioning for ≥3 minutes, safe withdrawal, and absence of device-associated adverse events (DAE). Secondary outcomes included injection parameters, hemorrhage displacement, visual outcomes, and complications.
RESULTS: Robot-assisted injection succeeded in all eyes; one required injection into the submacular hemorrhage because of anatomy. Mean injection duration was 178 ± 34 seconds (max 400), but the needle tip was maintained in the subretinal space ≥3 minutes in all cases. No DAE occurred. Retinotomies closed spontaneously without visible reflux. Mean bleb initiation and propagation pressures were 10.3 ± 3.2 and 3.0 [3.0-3.25] PSI, respectively; internal limiting membrane peeling reduced initiation pressure ( P < 0.05). Complete subfoveal displacement was achieved in 95%. Median BCVA improved from LogMAR 1.85 (counting fingers) to 0.66 (20/90) at 6 weeks ( P < 0.001). Adverse events included hyphema (5%), ocular hypertension (5%), vitreous hemorrhage (25%; 80% self-limited), RPE tear (20%), and recurrent submacular hemorrhage (5%).
CONCLUSION: Robot-assisted subretinal injection with Mynutia is feasible and safe, enabling stable, prolonged low-pressure delivery through attached retina, and may enhance precision and tissue preservation in subretinal therapies.